-continued

```
Leu Gln His His Cys Val Ile His Asp Ala Trp Ser Gly Leu Arg His
        275                 280                 285

Val Val Gln Leu Arg Ala Gln Glu Glu Phe Gly Gln Gly Glu Trp Ser
    290                 295                 300

Glu Trp Ser Pro Glu Ala Met Gly Thr Pro Trp Thr Glu Ser Arg Ser
305                 310                 315                 320

Pro Pro Ala Glu Asn Glu Val Ser Thr Pro Met Gln Ala Leu Thr Thr
                325                 330                 335

Asn Lys Asp Asp Asp Asn Ile Leu Phe Arg Asp Ser Ala Asn Ala Thr
            340                 345                 350

Ser Leu Pro Val Gln Asp
        355
```

What is claimed is:

1. A pharmaceutical formulation comprising: (i) a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R); (ii) histidine; and (iii) a carbohydrate.

2. The pharmaceutical formulation of claim **1**, wherein said carbohydrate is a sugar.

3. The pharmaceutical formulation of claim **2**, wherein said sugar is selected from the group consisting of sucrose, glucose, mannitol, lactose and trehalose.

4. The pharmaceutical formulation of claim **2**, wherein said sugar is sucrose.

5. The pharmaceutical formulation of claim **1**, further comprising a non-ionic surfactant.

6. The pharmaceutical formulation of claim **5**, wherein said non-ionic surfactant is selected from the group consisting of polysorbate 20, polysorbate 80 and polyoxyethylene sorbitan monooleate.

7. The pharmaceutical formulation of claim **6**, wherein said non-ionic surfactant is polysorbate 20.

8. The pharmaceutical formulation of claim **1**, further comprising arginine.

9. A pharmaceutical formulation comprising: (i) about 5 to 200 mg/mL of a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R); (ii) about 5 to 50 mM histidine; and (iii) about 1 to 20% sucrose.

10. The pharmaceutical formulation of claim **9**, further comprising: (iv) about 0.01 to 1% polysorbate 20.

11. The pharmaceutical formulation of claim **10** comprising: (i) about 25 to 200 mg/mL of a human antibody that specifically binds to hIL-6R; (ii) about 10 to 25 mM histidine; (iii) about 5 to 10% sucrose; and (iv) about 0.1 to 0.2% polysorbate 20.

12. The pharmaceutical formulation of claim **11**, further comprising: (v) about 5 to 100 mM arginine.

13. The pharmaceutical formulation of claim **12**, comprising about 25 to 50 mM arginine.

14. The pharmaceutical formulation of claim **11**, comprising: (i) about 100 mg/mL of a human antibody that specifically binds to hIL-6R; (ii) about 10 mM histidine; (iii) about 10% sucrose; and (iv) about 0.2% polysorbate 20.

15. The pharmaceutical formulation of claim **13**, comprising: (i) about 150 mg/mL of a human antibody that specifically binds to hIL-6R; (ii) about 25 mM histidine; (iii) about 5% sucrose; (iv) about 0.2% polysorbate 20; and (v) about 25 mM arginine.

16. The pharmaceutical formulation of claim **13**, comprising: (i) about 175 mg/mL of a human antibody that specifically binds to hIL-6R; (ii) about 25 mM histidine; (iii) about 5% sucrose; (iv) about 0.2% polysorbate 20; and (v) about 50 mM arginine.

17. The pharmaceutical formulation of claim **12** contained in a glass vial.

18. The pharmaceutical formulation of claim **12** contained in a syringe.

19. The pharmaceutical formulation of claim **12** contained in a microinfusor.

20. The pharmaceutical formulation of claim **18**, wherein said syringe comprises a fluorocarbon-coated plunger.

21. The pharmaceutical formulation of claim **18**, wherein said syringe is a low tungsten syringe.

22. The pharmaceutical formulation of claim **21**, wherein said syringe comprises a fluorocarbon-coated plunger.

23. The pharmaceutical formulation of claim **16**, wherein at least 90% of native form of said antibody is recovered after nine months of storage at 5° C., as determined by size exclusion-high performance liquid chromatography (SE-HPLC).

24. The pharmaceutical formulation of claim **23**, wherein at least 95% of native form of said antibody is recovered after nine months of storage at 5° C., as determined by size exclusion-high performance liquid chromatography (SE-HPLC).

25. The pharmaceutical formulation of claim **24**, wherein at least 96% of native form of said antibody is recovered after nine months of storage at 5° C., as determined by size exclusion-high performance liquid chromatography (SE-HPLC).

26. The pharmaceutical formulation of claim **16**, wherein the formulation exhibits a viscosity of less than about 15 cPoise.

27. The pharmaceutical formulation of claim **26**, wherein the formulation exhibits a viscosity of less than about 12 cPoise.

28. The pharmaceutical formulation of claim **27**, wherein the formulation exhibits a viscosity of less than about 9 cPoise.

29. The pharmaceutical formulation of claim **1**, wherein said human antibody that specifically binds to hIL-6R comprises a heavy chain variable region (HCVR) and a light chain variable region (LCVR), wherein the HCVR comprises heavy and light chain complementarity determining